4.7 Article

Oxidized Low-Density Lipoprotein Drives Dysfunction of the Liver Lymphatic System

Journal

Publisher

ELSEVIER INC
DOI: 10.1016/j.jcmgh.2020.09.007

Keywords

Oxidized LDL; Lymphangiogenesis; VEGFC; Permeability; Inflammation

Funding

  1. University of Colorado Anschutz GI
  2. Liver Innate Immune Program Pilot award
  3. Linda Crnic Institute Grand Challenge Pilot
  4. Ruth L. Kirschstein National Research Service Award [T32 DK067009]
  5. University of Colorado Anschutz Consortium for Fibrosis Research and Translation postdoctoral fellowship
  6. University of Colorado Anschutz Molecular Biology Graduate Program [GM008730-20S1]
  7. National Institutes of Health [R01 AI121209, DK125595, R00 AA025386]
  8. University of Colorado Outstanding Early Career Scholar
  9. RNA Biosciences Initiative Clinical Scholar Award
  10. Waterman Family Foundation for Liver Research

Ask authors/readers for more resources

This study focuses on how normal liver functions are affected during the development of nonalcoholic steatohepatitis (NASH) and the impact of inflammatory mediators on lymphatic vasculature in the liver. The findings suggest that in NASH, there is an expansion of the lymphatic vasculature which leads to downregulation of genes essential for lymphatic identity and function. Furthermore, exposure to oxidized low density lipoprotein (oxLDL) reduces lymphatic permeability in the liver, resulting in decreased protein homeostasis and increased inflammation during chronic liver disease.
BACKGROUND AND AIMS: As the incidence of nonalcoholic steatohepatitis (NASH) continues to rise, understanding how normal liver functions are affected during disease is required before developing novel therapeutics which could reduce morbidity and mortality. However, very little is understood about how the transport of proteins and cells from the liver by the lymphatic vasculature is affected by inflammatory mediators or during disease. METHODS: To answer these questions, we utilized a well-validated mouse model of NASH and exposure to highly oxidized low density lipoprotein (oxLDL). In addition to single cell sequencing multiplexed immunofluorescence and metabolomic analysis of liver lymphatic endothelial cells (LEC)s we evaluated lymphatic permeability and transport both in vitro and in vivo. RESULTS: Confirming similarities between human and mouse liver lymphatic vasculature in NASH, we found that the lymphatic vasculature expands as disease progresses and results in the downregulation of genes important to lymphatic identity and function. We also demonstrate, in mice with NASH, that fluorescein isothiocyanate (FITC) dextran does not accumulate in the liver draining lymph node upon intrahepatic injection, a defect that was rescued with therapeutic administration of the lymphatic growth factor, recombinant vascular endothelial growth factor C (rVEGFC). Similarly, exposure to oxLDL reduced the amount of FITC-dextran in the portal draining lymph node and through an LEC monolayer. We provide evidence that the mechanism by which oxLDL impacts lymphatic permeability is via a reduction in Prox1 expression which decreases lymphatic specific gene expression, impedes LEC metabolism and reorganizes the highly permeable lymphatic cell-cell junctions which are a defining feature of lymphatic capillaries. CONCLUSIONS: We identify oxLDL as a major contributor to decreased lymphatic permeability in the liver, a change which is consistent with decreased protein homeostasis and increased inflammation during chronic liver disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available